CANY
CELL

Caxton Associates (New York)’s PhenomeX Inc. Common Stock CELL Stock Holding History

Caxton Associates (New York)’s Portfolio CELL Stock Details CELL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-100,824
Closed -$270K – 675
2022
Q4 		$270K Buy
100,824
+82,324
+445% +$217K 0.02% 341
2022
Q3 		$53K Buy
+18,500
New +$78.7K 0.01% 457

Other funds holding CELL

NV
Northpond Ventures Bethesda, Maryland $43.7M AUM 27.27% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
NIMC
Nierenberg Investment Management Company Camas, Washington $201M AUM 36.3% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Caxton Associates (New York)'s CELL Position: Q1 2023 in Review

Caxton Associates (New York) sold out of PhenomeX Inc. Common Stock (CELL) in Q1 2023, closing a stake of 100,824 shares — an estimated $270K sold.

Caxton Associates (New York) first reported a position in CELL in Q3 2022 and held it in 2 quarters. The position peaked at $270K in Q4 2022. 102 funds tracked by Wall St. Rank hold CELL as of Q1 2023.

  • Caxton Associates (New York) reported no remaining PhenomeX Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Caxton Associates (New York) sold 100,824 PhenomeX Inc. Common Stock shares in Q1 2023, an estimated $270K.
  • Caxton Associates (New York) first reported a position in PhenomeX Inc. Common Stock in Q3 2022 and held it in 2 quarters.
  • Caxton Associates (New York)'s PhenomeX Inc. Common Stock position peaked at $270K in Q4 2022.
  • 102 funds tracked by Wall St. Rank held PhenomeX Inc. Common Stock as of Q1 2023.

Based on Caxton Associates (New York)'s 13F filing for Q1 2023, filed 15 May 2023.